High specificity of engineered T cells with third generation CAR (CD28-4-1BB-CD3-ζ) based on biotin-bound monomeric streptavidin for potential tumor immunotherapy
First, optimizing culture conditions would be essential before deploying UniCAR-T cells clinically. Moreover, we propose that third-generation UniCAR-T cells are excellent candidates for preclinical research due to their high specificity and multi-target anti-tumor cytotoxicity.
Authors
- Jorge Gallego-Valle (ORCID: https://orcid.org/0000-0002-1603-1720)
- María Castellà (ORCID: https://orcid.org/0000-0003-2062-0373)
- Rafael Correa‐Rocha (ORCID: https://orcid.org/0000-0003-3456-9986)
- Marjorie Pion (ORCID: https://orcid.org/0000-0002-6406-747X)
- Sergio Gil-Manso (ORCID: https://orcid.org/0000-0003-2480-3628)
- Europa Azucena González‐Navarro (ORCID: https://orcid.org/0000-0003-3310-5557)
- Manel Juan (ORCID: https://orcid.org/0000-0002-3064-1648)
- Verónica Astrid Pérez-Fernández
- Jesús Rosales-Magallares
Institutions
- Hospital Sant Joan de Déu Barcelona (ES)
- Hospital General Universitario Gregorio Marañón (ES)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-09-19
- DOI
- https://doi.org/10.3389/fimmu.2024.1448752
- Citations
- 5
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.41
Funders
- European Commission
- Instituto de Salud Carlos III
- European Regional Development Fund